Cytokinetics CEO Robert I. Blum disposes of $471,600 in common shares
Cytokinetics President and CEO Robert I. Blum exercised options for 7,500 shares at USD 10.6 on Oct. 12, 2026. He sold 7,500 shares at USD 62.88 the same day. * Directly held common stock position fell to 278,544 shares. * Directly held non-qualified stock options declined to 141,745. Disclaimer: This news brief was cr